Celgene

This phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…

This study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…

This phase 3 study tested an oral drug called azacitidine (CC-486) against standard treatments in 93 adults with a rare T-cell lymphoma that had relapsed or stopped responding. The main goal was to see if the drug could delay cancer progression or death. Participants were randoml…

This study tested a drug called luspatercept in 30 adults from China and Japan who have a bone marrow disorder (MDS) and need regular red blood cell transfusions. The goal was to see if the drug could help them go without transfusions for at least 8 weeks. The drug works by helpi…

This study looks at the long-term safety of a drug called CC-93538 (cendakimab) for people with eosinophilic esophagitis, a condition that causes inflammation in the esophagus. It enrolled 367 adults and teens who had already taken part in earlier studies of the same drug. The ma…

This study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…

This study tested a therapy called bb2121, made from a patient's own immune cells that are reprogrammed to attack myeloma cells. It included over 300 people with multiple myeloma that had returned or was high-risk. The goal was to see if the treatment could shrink tumors and cont…

This study looked at the long-term safety and effectiveness of an oral medication called RPC1063 for people with moderate to severe ulcerative colitis. It included 877 adults who had already taken part in earlier RPC1063 trials. The goal was to see how well the drug controls the …

This early-stage trial tested a new drug called CC-94676 in 131 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to standard hormone therapy. The main goal was to check safety and find the right dose, while also looking for signs that t…

This study tested a drug called CC-93538 (Cendakimab) in 48 Japanese adults and adolescents with eosinophilic gastroenteritis, a condition where certain white blood cells build up in the digestive tract causing pain and other symptoms. The trial was randomized and placebo-control…

This study tested two doses of a daily pill called ozanimod in 198 Japanese adults with moderate to severe ulcerative colitis. The goal was to see if it could reduce symptoms and inflammation better than a placebo. The trial also checked long-term safety. Ozanimod works by calmin…

This study followed over 900 newly diagnosed multiple myeloma patients who were not eligible for a stem cell transplant. Researchers compared heart-related side effects between those treated with lenalidomide (Revlimid) and those receiving other treatments. The goal was to better…

This completed Phase 1 study looked at how the drug golcadomide is processed in the body of people with moderate or severe liver impairment compared to healthy volunteers. 29 adults received a single dose, and researchers measured drug levels and safety. The goal is to understand…